Monte Rosa Therapeutics (GLUE) Times Interest Earned (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Times Interest Earned of -$0.41 for Q1 2026, down 106.82% year-over-year from $5.98 in Q1 2025, and up 5.43% quarter-over-quarter from -$0.43 in Q4 2025.
Monte Rosa Therapeutics (GLUE) Times Interest Earned (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Times Interest Earned history runs 7 years deep, the most recent figure standing at -$0.41 for Q1 2026.
- In Q1 2026, Times Interest Earned fell 106.82% year-over-year to -$0.41; the TTM figure through Mar 2026 stood at -$1.21 (down 317.97% YoY), while the FY2025 annual figure was -$0.47, up 58.16% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$0.41, up from -$0.43 in the prior quarter.
- The five-year high for Times Interest Earned was $5.98 in Q1 2025, with the low at -$2.61 in Q4 2022.
- The 5-year median for Times Interest Earned is -$0.52 (2024), against an average of -$0.36.
- The sharpest annual moves came in 2022 and 2025: Times Interest Earned tumbled 682.2% in 2022, then soared 1250.83% in 2025.
- Monte Rosa Therapeutics' Times Interest Earned stood at -$2.61 in 2022, then jumped by 75.49% to -$0.64 in 2023, then surged by 277.91% to $1.14 in 2024, then slumped by 137.88% to -$0.43 in 2025, then increased by 5.43% to -$0.41 in 2026.
- Business Quant data shows GLUE's Times Interest Earned at -$0.41 in Q1 2026, -$0.43 in Q4 2025, and -$2.08 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | -0.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.21 |
| Mar 31, 2026 | -0.41 |
| Dec 31, 2025 | -0.43 |
| Sep 30, 2025 | -2.08 |
| Jun 30, 2025 | -0.27 |
| Mar 31, 2025 | 5.98 |
| Dec 31, 2024 | 1.14 |
| Sep 30, 2024 | -1.33 |
| Jun 30, 2024 | -1.56 |
| Mar 31, 2024 | -0.52 |
| Dec 31, 2023 | -0.64 |
| Sep 30, 2023 | -0.52 |
| Jun 30, 2023 | -0.51 |
| Mar 31, 2023 | -0.47 |
| Dec 31, 2022 | -2.61 |
| Sep 30, 2022 | -0.39 |
| Jun 30, 2022 | -0.92 |
| Mar 31, 2022 | -0.60 |
| Dec 31, 2021 | -0.33 |
| Sep 30, 2021 | -0.24 |